Teleflex Incorporated (TFX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Teleflex Incorporated ( TFX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Liam Kelly - Chairman, President & CEO Conference Call Participants Matthew Taylor - Jefferies LLC, Research Division Presentation Matthew Taylor Jefferies LLC, Research Division Great. Thanks for joining us here for our next session.
Don't Overlook Teleflex (TFX) International Revenue Trends While Assessing the Stock
Explore Teleflex's (TFX) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Teleflex Incorporated (TFX) Discusses Strategic Rationale and Portfolio Overview of Acquired Vascular Intervention Business Transcript
Teleflex Incorporated ( TFX ) Discusses Strategic Rationale and Portfolio Overview of Acquired Vascular Intervention Business November 14, 2025 8:00 AM EST Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy Development Thierry Glauser Christopher Buller Liam Kelly - Chairman, President & CEO Conference Call Participants Kevin Croce Elliot Smith Patrick Wood - Morgan Stanley, Research Division Ravi Misra - Truist Securities, Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Teleflex Vascular Intervention Investor Meeting. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly.
TFX Stock Falls Despite Q3 Earnings and Revenue Beat, '25 View Down
Teleflex posts strong Q3 earnings and revenue beats but trims 2025 outlook, sending shares slightly lower.
Teleflex Incorporated (TFX) Q3 2025 Earnings Call Transcript
Teleflex Incorporated ( TFX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy Development Liam Kelly - Chairman, President & CEO John Deren - Executive VP & CFO Conference Call Participants Michael Matson - Needham & Company, LLC, Research Division Matthew Taylor - Jefferies LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Ravi Misra - Truist Securities, Inc., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Patrick Wood - Morgan Stanley, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Teleflex Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly.
Teleflex (TFX) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates
Teleflex (TFX) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $3.38 per share. This compares to earnings of $3.49 per share a year ago.
TFX vs. PEN: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
Should Value Investors Buy Teleflex (TFX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Teleflex (TFX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TFX or SONVY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Teleflex (TFX) or SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
Teleflex Stock Gains Following Barrigel's Launch in Japan
TFX stock jumps 3.7% after launching Barrigel in Japan, marking a milestone in its global expansion strategy.
